title: Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life.
abstract: This retrospective multicenter analysis was aimed to evaluate clinical activity and tolerability of eribulin in pretreated metastatic breast cancer patients in clinical practice. Patients treated with eribulin from January 2012 to July 2013 were enrolled in the observational study from 10 italian hospitals. Tumor and toxicity evaluation were performed according to Agenzia Italiana Farmaco. One-hundred and thirteen patients were included in the study. Median age 62 years old. 71.7 % of the patients had visceral involvement and the majority had a burden of disease involving two or more organs with a median number of 2 (1-6). The median number of previous chemotherapy regimens for advanced disease was 3 (1-10). Median number of eribulin cycles was 4 (1-27). Overall response rate was 24 % (95 % CI 16.0-31.8). Clinical benefit rate, was 35.4 % (95 % CI 26.6-44.2). At a median follow-up of 29.6 months (8.3-41.9) the median progression free survival was 3.3 months (0.6-26.7; 95 % CI 2.4-4.2), and the median overall survival 11.6 months (0.6-33.3; 95 % CI 8.7-14.5). No correlation was recorded between subtypes in terms of ORR and CBR. Toxicity was manageable. Main common grade 3-4 toxicities were neutropenia (19.4 %), febrile neutropenia (0.9 %), asthenia (3.5 %), abnormal liver function test (1.8 %), stomatitis (0.9 %). Our results confirm that treatment with eribulin is feasible and safe in real-world patients.
authors.affiliation: Medical Oncology, A.O. Ospedale di Insegnamento S. Croce e Carle, V. M. Coppino, 26, 12100 Cuneo, Italy.
authors.forename: Ornella
authors.initials: O
authors.lastname: Garrone
authors.affiliation: Investigative Clinical Oncology, Fondazione del Piemonte per l'Oncologia, Candiolo Cancer Institute (IRCCS), Strada Provinciale 142, 10060 Candiolo, Turin, Italy.
authors.forename: Filippo
authors.initials: F
authors.lastname: Montemurro
authors.affiliation: Medical Oncology, A.O.U. Maggiore della Carità, C. G. Mazzini, 28, 28100 Novara, Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Saggia
authors.affiliation: Department of Oncology, A.O. Fatebenefratelli & Oftalmico, C. di Porta Nuova, 25, 20121 Milan, Italy.
authors.forename: Nicla
authors.initials: N
authors.lastname: La Verde
authors.affiliation: Medical Oncology, A.O. Ospedale di Insegnamento S. Croce e Carle, V. M. Coppino, 26, 12100 Cuneo, Italy.
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Vandone
authors.affiliation: Department of Medical Oncology 2, A.O.U. Città della Salute e della Scienza, C. Bramante, 88, 10126 Turin, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Airoldi
authors.affiliation: Medical Oncology, Ospedale Cardinal Massaia, C. D. Alighieri, 201, 14100 Asti, Italy.
authors.forename: Enrico
authors.initials: E
authors.lastname: De Conciliis
authors.affiliation: Breast Unit, A.O.U. Città della Salute e della Scienza, C. Bramante, 88, 10126 Turin, Italy.
authors.forename: Michela
authors.initials: M
authors.lastname: Donadio
authors.affiliation: Radiotherapy Oncology, A.O. Ospedale di Insegnamento S. Croce e Carle, V. M. Coppino, 26, 12100 Cuneo, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Lucio
authors.affiliation: Medical Oncology, Ospedale Ivrea, Piazza Credenza, 2, 10015 Ivrea, Italy.
authors.forename: Maria Antonia
authors.initials: MA
authors.lastname: Polimeni
authors.affiliation: Medical Oncology, Ospedale S. Spirito, V. G. Giolitti, 2, 15033 Casale Monferrato, Italy.
authors.forename: Maria Vittoria
authors.initials: MV
authors.lastname: Oletti
authors.affiliation: Department of Oncology, Ospedale degli Infermi, V. Ponderanesi, 2, 13875 Ponderano, Italy.
authors.forename: Alice
authors.initials: A
authors.lastname: Giacobino
authors.affiliation: Medical Oncology, A.O. Ospedale di Insegnamento S. Croce e Carle, V. M. Coppino, 26, 12100 Cuneo, Italy.
authors.forename: Marco Carlo
authors.initials: MC
authors.lastname: Merlano
keywords: Eribulin; Metastatic breast cancer; Real life; Toxicity
references.citation: Cancer Res. 2004 Aug 15;64(16):5760-6
references.pmid: 15313917
references.citation: J Cancer. 2014 Mar 20;5(5):320-7
references.pmid: 24723974
references.citation: Mol Cancer Ther. 2008 Jul;7(7):2003-11
references.pmid: 18645010
references.citation: Lancet. 2011 Mar 12;377(9769):914-23
references.pmid: 21376385
references.citation: Ann Oncol. 2012 Jun;23 (6):1441-8
references.pmid: 21989327
references.citation: Future Oncol. 2014 Feb;10 (3):363-76
references.pmid: 24367990
references.citation: Clin Breast Cancer. 2014 Dec;14 (6):405-12
references.pmid: 25024001
references.citation: Mol Cancer Ther. 2005 Jul;4(7):1086-95
references.pmid: 16020666
references.citation: Mol Pharmacol. 2006 Dec;70(6):1866-75
references.pmid: 16940412
references.citation: Ann Oncol. 2013 Sep;24(9):2206-23
references.pmid: 23917950
references.citation: Breast Cancer Res Treat. 2014 Jul;146(2):321-8
references.pmid: 24699910
references.citation: Oncologist. 2014 Apr;19(4):318-27
references.pmid: 24682463
references.citation: Future Oncol. 2014 Feb;10 (2):233-9
references.pmid: 24490609
references.citation: J Clin Oncol. 2009 Jun 20;27(18):2954-61
references.pmid: 19349550
references.citation: J Clin Oncol. 2010 Sep 1;28(25):3922-8
references.pmid: 20679609
references.citation: Cancer Res. 2001 Feb 1;61(3):1013-21
references.pmid: 11221827
references.citation: Breast. 2014 Oct;23(5):489-502
references.pmid: 25244983